Condition: Soft Tissue Sarcoma (STS) · Bronchoalveolar Lavage (BAL) · Bronchoalveolar Lavage Fluid · Sponsor: University Health Network, Toronto
This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.
This description comes directly from the study's public registry record.
David Shultz · 416-946-4501 · david.shultz@uhn.ca
Always discuss trial participation with your own doctor first.
| Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06815666